keyword
https://read.qxmd.com/read/38501406/-efficacy-of-navel-application-of-jianpiwenyang-gel-for-chronic-diarrhea-of-spleen-and-stomach-weakness-type-a-randomized-controlled-trial-and-analysis-of-the-mechanism
#21
JOURNAL ARTICLE
Y Cui, D Wang, D Xie, H Wang, R Xu, X Tang, Y Zhang
OBJECTIVE: To investigate the efficacy of Jianpiwenyang Gel (SSWYG) for treating chronic diarrhea and explore its therapeutic mechanism. METHODS: Eighty patients with chronic diarrhea of spleen and stomach weakness type were randomized into two groups for interventions with lifestyle adjustment and treatment with bifid triple viable capsules (control group, n =40) or naval application with SSWYG (treatment group, n =40) for one week, after which symptoms of chronic diarrhea were evaluated...
February 20, 2024: Nan Fang Yi Ke da Xue Xue Bao, Journal of Southern Medical University
https://read.qxmd.com/read/38500074/triple-platelet-inhibition-in-intracranial-thrombectomy-with-additional-acute-cervical-stent-angioplasty-due-to-tandem-lesion-a-retrospective-single-center-analysis
#22
JOURNAL ARTICLE
Ali Khanafer, Hans Henkes, Philipp Bücke, Florian Hennersdorf, Hansjörg Bäzner, Michael Forsting, Philipp von Gottberg
BACKGROUND: Acute stroke treatment with intracranial thrombectomy and treatment of ipsilateral carotid artery stenosis/occlusion ("tandem lesion", TL) in one session is considered safe. However, the risk of stent restenosis after TL treatment is high, and antiplatelet therapy (APT) preventing restenosis must be well balanced to avoid intracranial hemorrhage. We investigated the safety and 90-day outcome of patients receiving TL treatment under triple-APT, focused on stent-patency and possible disadvantageous comorbidities...
March 18, 2024: BMC Neurology
https://read.qxmd.com/read/38497762/clinical-outcomes-of-functional-endoscopic-sinus-surgery-in-cystic-fibrosis-patients-a-single-centre-experience
#23
JOURNAL ARTICLE
Y Devabalan, R Towning, J Magill, H Saleh, C Rennie
BACKGROUND: Endoscopic sinus surgery (ESS) is an established surgical option for cystic fibrosis (CF) patients with chronic rhinosinusitis that is refractory to conventional medical management. Objective and subjective evidence of benefit of ESS in this cohort of patients is currently conflicting in the literature. METHODOLOGY: A single center retrospective study was undertaken of all CF patients (transplanted and non-transplanted) over the age of 16 who underwent an ESS over a six-year period from 2015 to 2021...
March 18, 2024: Rhinology
https://read.qxmd.com/read/38495972/the-role-of-probiotics-in-the-eradication-of-helicobacter-pylori-and-overall-impact-on-management-of-peptic-ulcer-a-study-involving-patients-undergoing-triple-therapy-in-bangladesh
#24
JOURNAL ARTICLE
Taslima Zaman, Ahsanul Haq, Rahnuma Ahmad, Susmita Sinha, Kona Chowdhury, Sultana Parvin, Mostofa Imran, Zaman U Humayra, Santosh Kumar, Mainul Haque
Background Helicobacter pylori infection has been identified to cause constantly recurring inflammation, leading to gastrointestinal tract disorders, including carcinoma. The standard triple therapy (STT), used to eradicate H. pylori, includes two antimicrobials and a proton pump inhibitor for two weeks. Other drug regimens have also been developed since H. pylori exhibits antimicrobial resistance. These regimens, including probiotics, have been shown to lower adverse drug reactions (ADR), improve drug adherence, exert bacteriostatic effect, and reduce inflammation...
March 2024: Curēus
https://read.qxmd.com/read/38472501/feasibility-of-targeted-therapies-in-the-adjuvant-setting-of-early-breast-cancer-in-men-real-world-data-from-a-population-based-registry
#25
JOURNAL ARTICLE
M L Frevert, D Dannehl, L Jansen, S Hermann, H Schäffler, S Huwer, W Janni, I Juhasz-Böss, A D Hartkopf, F-A Taran
BACKGROUND: Following the positive iDFS and OS results of the phase III clinical trials monarchE, NATALEE and OlympiA, new oral anticancer agents (the CDK4/6 inhibitors abemaciclib, ribociclib as well as the PARP inhibitor olaparib) have recently been introduced into the treatment of high-risk early breast cancer (eBC). However, only few male patients were included in these trials (0.4%, 0.6% and 0.3%, respectively). The objective of this real-world analysis was to determine the proportion of male patients with eBC fulfilling the clinical high-risk criteria of above-mentioned trials...
March 12, 2024: Archives of Gynecology and Obstetrics
https://read.qxmd.com/read/38468323/her2-low-and-tumor-infiltrating-lymphocytes-in-triple-negative-breast-cancer-are-they-connected
#26
MULTICENTER STUDY
Ximena Baez-Navarro, Nadine S van den Ende, Anh H Nguyen, Renata Sinke, Pieter Westenend, Johannes Bastiaan van Brakel, Claudia Stobbe, Johan Westerga, Carolien H M van Deurzen
Most patients with triple-negative breast cancer (TNBC) are not candidates for targeted therapy, leaving chemotherapy as the primary treatment option. Recently, immunotherapy has demonstrated promising results in TNBC, due to its immunogenicity. In addition, a novel antibody-drug conjugate, namely, trastuzumab-deruxtecan, has shown effectiveness in TNBC patients with low-HER2 expression (HER2-low). These novel treatment options raise the question about the potential association between the density of stromal tumor-infiltrating lymphocytes (sTILs) and the level of HER2 expression...
March 11, 2024: Breast Cancer Research: BCR
https://read.qxmd.com/read/38464382/efficacy-of-metformin-and-electrical-pulses-in-breast-cancer-mda-mb-231-cells
#27
JOURNAL ARTICLE
Praveen Sahu, Ignacio G Camarillo, Raji Sundararajan
AIM: Triple-negative breast cancer (TNBC) is a very aggressive subset of breast cancer, with limited treatment options, due to the lack of three commonly targeted receptors, which merits the need for novel treatments for TNBC. Towards this need, the use of metformin (Met), the most widely used type-2 diabetes drug worldwide, was explored as a repurposed anticancer agent. Cancer being a metabolic disease, the modulation of two crucial metabolites, glucose, and reactive oxygen species (ROS), is studied in MDA-MB-231 TNBC cells, using Met in the presence of electrical pulses (EP) to enhance the drug efficacy...
2024: Exploration of targeted anti-tumor therapy
https://read.qxmd.com/read/38463026/optimized-sequential-therapy-vs-10-and-14-d-concomitant-therapy-for-eradicating-helicobacter-pylori-a-randomized-clinical-trial
#28
RANDOMIZED CONTROLLED TRIAL
Hassan Seddik, Jihane Benass, Sanaa Berrag, Asmae Sair, Reda Berraida, Hanae Boutallaka
BACKGROUND: A cure for Helicobacter pylori ( H. pylori ) remains a problem of global concern. The prevalence of antimicrobial resistance is widely rising and becoming a challenging issue worldwide. Optimizing sequential therapy seems to be one of the most attractive strategies in terms of efficacy, tolerability and cost. The most common sequential therapy consists of a dual therapy [proton-pump inhibitors (PPIs) and amoxicillin] for the first period (5 to 7 d), followed by a triple therapy for the second period (PPI, clarithromycin and metronidazole)...
February 14, 2024: World Journal of Gastroenterology: WJG
https://read.qxmd.com/read/38459869/bismuth-add-on-improves-the-efficacy-of-2-week-tegoprazan-based-triple-therapy-for-first-line-helicobacter-pylori-eradication-a-real-world-evidence-study
#29
JOURNAL ARTICLE
Jun-Hyung Cho
BACKGROUND: This study aimed to investigate the efficacy of bismuth added to a 2-week triple therapy consisting of tegoprazan (TPZ), amoxicillin, and clarithromycin for first-line Helicobacter pylori eradication. RESEARCH DESIGN AND METHODS: We reviewed the retrospective data of patients who received a 2-week TPZ-based triple therapy with or without 300 mg bismuth twice daily. The primary endpoint was the H. pylori eradication rate of adding bismuth to the TPZ-based triple regimen (TAC-B group), compared to no bismuth added (TAC group)...
March 9, 2024: Expert Review of Anti-infective Therapy
https://read.qxmd.com/read/38458842/impact-of-anti-estrogen-therapy-on-early-cardiovascular-referrals-tests-and-medications-in-premenopausal-women-with-operable-breast-cancer
#30
JOURNAL ARTICLE
Emily Douglas, Beverly Levine, Ahmer Ansari, Katherine Ansley, Susan Melin, Carolyn J Park, Karl Richardson, Sarah Hatcher, Ralph B D'Agostino, Jennifer H Jordan, Alexandra Thomas
INTRODUCTION: Premenopausal women with high-risk hormone receptor (HR)-positive breast cancer often receive ovarian function suppression (OFS) and anti-estrogen therapy which induces near complete estrogen deprivation (NCED). This treatment improves recurrence-free survival but may increase cardiovascular risk. We sought to identify patterns of cardiovascular care and outcomes in premenopausal women with operable breast cancer. METHODS: Premenopausal women ≤ 50 years of age with stage I-III HR-positive or triple negative breast cancer (TNBC) were identified by retrospective review...
February 16, 2024: Clinical Breast Cancer
https://read.qxmd.com/read/38455644/efficacy-and-tolerability-of-helicobacter-pylori-eradication-regimes-in-south-kivu-eastern-of-the-democratic-republic-of-congo-a-single-center-observational-study
#31
JOURNAL ARTICLE
Tony A Shindano, Manix I Masimango, Antoine S Kishabongo
BACKGROUND AND AIMS: Treating Helicobacter pylori  infections has become a major challenge due to increased antibiotic resistance. The aim of this study was to investigate the efficacy and tolerability of the main standard regimens recommended for H. pylori eradication in Bukavu, Eastern of the Democratic Republic of Congo. METHODS: The study enrolled patients with evidence of H. pylori infection in histological examination or serology testing combined with a positive fecal antigen test...
March 2024: Health Science Reports
https://read.qxmd.com/read/38450675/auranofin-loaded-chitosan-nanoparticles-demonstrate-potency-against-triple-negative-breast-cancer
#32
JOURNAL ARTICLE
Maame Abena O Afrifa, Jong H Kim, Kathryn A Pitton, Chibuzor Olelewe, Adedamola S Arojojoye, Douglas R Strachan, Mark A Suckow, Samuel G Awuah
Triple-negative breast cancer (TNBC) remains a clinical challenge due to molecular, metabolic, and genetic heterogeneity as well as the lack of validated drug targets. Thus, therapies or delivery paradigms are needed. Gold-derived compounds including the FDA-approved drug, auranofin have shown promise as effective anticancer agents against several tumors. To improve the solubility and bioavailability of auranofin, we hypothesized that the nanodelivery of auranofin using biodegradable chitosan modified polyethylene glycol (PEG) nanoparticles (NPs) will enhance anticancer activity against TNBC by comparing the best nanoformulation with the free drug...
March 7, 2024: ACS Applied Bio Materials
https://read.qxmd.com/read/38447813/glucose-responsive-insulin-microneedle-patches-for-long-acting-delivery-and-release-visualization
#33
JOURNAL ARTICLE
Ye He, Nanxi Chen, Mingming Zang, Jinghai Zhang, Youxi Zhang, Honglllyan Lu, Qinfu Zhao, Yuling Mao, Yue Yuan, Siling Wang, Yikun Gao
Limited drug loading and incomplete drug release are two major obstacles that traditional polymeric microneedles (MNs) have to overcome. For smart controlled-release MNs, since drug release duration is uncertain, a clear indication of the finish of drug release is also important for patient guidance on the timing of the next dose. In this study, MN with a triple structure of a glucose-responsive shell, loaded insulin powders and a colored propelling inner core (inspired by the mechanism of osmotic pump) was innovatively constructed...
March 4, 2024: Journal of Controlled Release
https://read.qxmd.com/read/38447130/retinal-vasculitis-in-a-patient-with-hansen-s-disease
#34
JOURNAL ARTICLE
Shravan V Savant, Sarkis H Soukiasian, Richard F Spaide, Kendra A Klein-Mascia
PURPOSE: Hansen's disease is endemic in over 140 countries worldwide and a potentially blinding condition. We describe a case of retinal vasculitis in a patient with Hansen's disease with concomitant positive antiphospholipid antibody serology, a potentially under-reported complication in this setting. METHODS: A 37-year-old Brazilian man systemically stable on triple therapy (clofazimine, rifampin, dapsone) for Hansen's disease presented for a comprehensive ophthalmic evaluation...
March 4, 2024: Retinal Cases & Brief Reports
https://read.qxmd.com/read/38440143/-in-vitro-anti-helicobacter-pylori-activity-and-the-underlining-mechanism-of-an-empirical-herbal-formula-hezi-qingyou
#35
JOURNAL ARTICLE
Zhong Feng, Hui Li, Yajie Hao, Chang Peng, Ling Ou, Junwei Jia, Mingjin Xun, Yuanjing Zou, Meiyun Chen, Guimin Zhang, Meicun Yao
BACKGROUND: Helicobacter pylori ( H. pylori ) is thought to primarily colonize the human stomach and lead to various gastrointestinal disorders, such as gastritis and gastric cancer. Currently, main eradication treatment is triple or quadruple therapy centered on antibiotics. Due to antibiotic resistance, the eradication rate of H. pylori is decreasing gradually. Therefore, searching for anti- H. pylori drugs from herbal sources has become a strategy for the treatment. Our team proposed a Hezi Qingyou Formula (HZQYF), composed of Chebulae Fructus, Ficus hirta Vahl and Cloves, and studied its anti- H...
2024: Frontiers in Microbiology
https://read.qxmd.com/read/38439112/docosahexaenoic-acid-dha-impairs-hypoxia-induced-cellular-and-exosomal-overexpression-of-immune-checkpoints-and-immunomodulatory-molecules-in-different-subtypes-of-breast-cancer-cells
#36
JOURNAL ARTICLE
Sepideh Maralbashi, Cynthia Aslan, Houman Kahroba, Milad Asadi, Mohammad Sadegh Soltani-Zangbar, Navideh Haghnavaz, Farhad Jadidi, Farhad Salari, Tohid Kazemi
BACKGROUND: Tumor cells express immune-checkpoint molecules to suppress anti-tumor immune responses. In part, immune evasion takes place by secreting exosomes bearing immune-checkpoint and immunomodulatory molecules and their inducing and/or regulating agents e.g., microRNAs (miRs). This study aimed to evaluate the effects of omega-3 fatty acid, docosahexaenoic acid (DHA), on the expression of some selected immune-checkpoint and immunomodulatory molecules and their regulating miRs under both normoxic and hypoxic conditions in triple negative (TNBC) invasive and triple positive non-invasive breast cancer cell lines...
March 4, 2024: BMC Nutrition
https://read.qxmd.com/read/38432130/everolimus-decreases-u-13-c-glucose-utilization-by-pyruvate-carboxylase-in-breast-cancer-cells-in-vitro-and-in-vivo
#37
JOURNAL ARTICLE
Gerke Ariaans, Jiske F Tiersma, Bernardus Evers, Albert Gerding, Stijn J H Waaijer, Remco A Koster, Daan J Touw, Barbara M Bakker, Dirk-Jan Reijngoud, Steven de Jong, Mathilde Jalving
Reprogrammed metabolism is a hallmark of cancer, but notoriously difficult to target due to metabolic plasticity, especially in response to single metabolic interventions. Combining mTOR inhibitor everolimus and mitochondrial complex 1 inhibitor metformin results in metabolic synergy in in vitro models of triple-negative breast cancer. Here, we investigated whether the effect of this drug combination on tumor size is reflected in changes in tumor metabolism using [U-13 C]glucose labeling in an MDA-MB-231 triple negative breast cancer xenograft model...
March 2, 2024: Biomedicine & Pharmacotherapy
https://read.qxmd.com/read/38422625/2023%C3%A2-year-in-review-early-breast-cancer
#38
JOURNAL ARTICLE
Guilherme Nader-Marta, Ann H Partridge
The results of several studies aiming to tailor early breast cancer treatment to individual risk were released in 2023. Axillary lymph node dissections and radiotherapy may be safely omitted in carefully selected patients. Sustained benefit from adjuvant CDK4/6 inhibitors was observed in high-risk hormone receptor-positive disease and the addition of immunotherapy to neoadjuvant chemotherapy improved pathological response. Continued benefit from perioperative pembrolizumab was reported in patients with triple negative breast cancer, while atezolizumab did not improve the risk of recurrence either pre- or postoperatively...
April 2024: Breast: Official Journal of the European Society of Mastology
https://read.qxmd.com/read/38411303/a-pilot-study-evaluating-high-dose-esomeprazole-bismuth-subcitrate-and-amoxicillin-for-eradicating-helicobacter-pylori-infection-in-iran
#39
JOURNAL ARTICLE
Sepehr Tirgar Fakheri, Hajar Shokri-Afra, David Y Graham, Zohreh Bari, Hafez Fakheri
BACKGROUND: Helicobacter pylori (H. pylori) is strongly associated with peptic ulcer disease and gastric cancer. We evaluated two triple therapy regimens comprising esomeprazole, high dose bismuth, and different doses of amoxicillin for first-line H. pylori eradication. MATERIALS AND METHODS: Two hundred patients with dyspepsia and naive H. pylori infection were randomly assigned into two groups (n = 100). Both groups were treated for 14 days similarly with esomeprazole (40 mg, twice daily) and bismuth subcitrate (240 mg, three times daily), but the dose of amoxicillin was varied between Groups A (750 mg) and B (1000 mg) three times daily...
2024: Helicobacter
https://read.qxmd.com/read/38410339/clinical-characteristics-and-management-of-triple-negative-breast-cancer-tnbc-in-jordan-a-retrospective-analysis
#40
JOURNAL ARTICLE
Hussein Al Husban, Anas Al Rabadi, Ala H Odeh, Kahled Abu Rumman, Feras Alkhawaldeh, Haneen Noures, Mohammad Abo Ashoor, Anas Abu Rumman, Mousa Atmeh, Mohannad Bawaneh
Introduction Triple-negative breast cancer (TNBC) is known for its aggressive nature and poor prognosis. Despite its responsiveness to chemotherapy, TNBC presents challenges in terms of survival, recurrence, and mortality rates, particularly in diverse populations. Limited research in the Middle East hampers comprehensive understanding and tailored management. Methods A retrospective study at the King Hussein Medical Center in Jordan between the period 2009 to 2023 explored TNBC patients (n=110) who underwent adjuvant chemotherapy after local excision or modified radical mastectomy (MRM)...
January 2024: Curēus
keyword
keyword
49252
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.